Novartis Ag (NVSEF) Payables (2009 - 2025)
Novartis Ag (NVSEF) posted Payables of $5.1 billion for Q4 2025, up 14.03% sequentially from $4.5 billion in Q2 2025, and up 1389.28% YoY from $345.0 million in Q4 2024.
Novartis Ag (NVSEF) Payables (2009 - 2025) Analysis & Trends
Novartis Ag (NVSEF) has 14 years of Payables data on file, last reported at $5.1 billion in Q4 2025.
- Quarterly Payables rose 1389.28% year-over-year to $5.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 billion (up 1389.28% YoY) and the FY2025 annual result came in at $5.1 billion, up 1389.28% from the prior year.
- Payables grew to $5.1 billion in Q4 2025 per NVSEF's latest filing, from $4.5 billion in the prior quarter.
- The five-year high for Payables was $6.5 billion in Q4 2021, with the low at -$290.0 million in Q3 2024.
- Average Payables over 5 years is $2.1 billion, with a median of $345.0 million recorded in 2024.
- Year-over-year, Payables slumped 2166.67% in 2022 and jumped 7967.65% in 2023.
- Novartis Ag's Payables stood at $6.5 billion in 2021, then dropped by 6.87% to $6.0 billion in 2022, then sank by 93.46% to $393.0 million in 2023, then declined by 12.21% to $345.0 million in 2024, then jumped by 1389.28% to $5.1 billion in 2025.
- Business Quant data shows NVSEF's Payables at $5.1 billion in Q4 2025, $4.5 billion in Q2 2025, and $345.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.03 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 27.92 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.77 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -22.55 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 6.01 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Novartis Ag | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.14 Bn |
| Jun 30, 2025 | 4.51 Bn |
| Dec 31, 2024 | 345.00 Mn |
| Sep 30, 2024 | -290.00 Mn |
| Jun 30, 2024 | 4.15 Bn |
| Dec 31, 2023 | 393.00 Mn |
| Jun 30, 2023 | 5.35 Bn |
| Dec 31, 2022 | 6.01 Bn |
| Jun 30, 2022 | -68.00 Mn |
| Dec 31, 2021 | 6.45 Bn |
| Sep 30, 2021 | -3.00 Mn |
| Jun 30, 2021 | -3.00 Mn |
| Mar 31, 2021 | -3.00 Mn |
| Dec 31, 2020 | 832.00 Mn |
| Jun 30, 2020 | -144.00 Mn |
| Dec 31, 2019 | 541.00 Mn |
| Jun 30, 2019 | -9.00 Mn |
| Mar 31, 2019 | -6.00 Mn |
| Dec 31, 2018 | 6.26 Bn |
| Jun 30, 2018 | 5.49 Bn |